| Description | 919 amino acids (NCBI: P10275), MW = 99,187.57 daltons; -1.5 charge with an isoelectric pt = 6.3797; 10.6 kb AR transcript (NCBI: NM_000044 - partial sequence): 1.1kb 5' Untranslated Region (UTR) followed by the 2.7 kb Open Reading Frame (ORF) followed by the 6.8kb 3' UTR.
AR: AR isoform 1 [Homo sapiens] NP_000035 920 aa
AR45: AR isoform 2 [Homo sapiens] NP_001011645 388 aa
The AR coding sequence contains variable poly-aminoacid repeats in the amino-terminal domain:
1. poly-glutamine (CAG: Glu-Q): avg 22 repeats with normal polymorphic range from 8 to 35, shorter (<18) associated with increased AR transactivation and prostate cancer risk. CAG repeats in spinal and bulbar muscular atrophy patients range from 38 to 62.
2. poly-proline (Pro-P): avg 8.
3. poly-glycine (GGC: Gly-G): avg 23, with normal range from 10 to 31. |
| Expression | Embryonic tissue, prostate, testis, liver, eye, kidney, adrenal glands, thyroid, heart, breast/mammary gland, uterus, skeletal muscle, specific regions of the brain (CNS) including spinal and bulbar motor neurons. |
| Localisation | Cytoplasm and nucleus |
| Function | AR is a member of the steroid hormone receptor family of ligand-dependent nuclear receptors. AR functions include gene expression via actions as a DNA-binding transcription factor, cell cycle/proliferation regulation, cell-to-cell signaling, and intracellular signal transduction, leading to the regulation of biological processes such as development, cellular proliferation, differentiation and apoptosis. Some of the main target genes transcriptionally regulated by AR include AR, prostate specific antigen (PSA/hKlk3), hKlk2, hKlk4, prostate specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), cell cycle regulator p27, vascular endothelial growth factor (VEGF), TMPRSS2, and Nkx3.1.
Prostate organogenesis: The presence of AR is required in the mesodermal-derived embryonic urogenital sinus mesenchyme to trigger branching morphogenesis of endodermal-derived epithelial cells in the presence of androgens; subsequent AR expression in the developing epithelium drives secretory protein production. AR also plays an important role in the development of primary and secondary sexual characteristics, spermatogenesis, hormonal regulation of sexual drive, muscle growth, and male patterning of the brain.
Recent identification of the gene fusion between the 5' end of the AR-regulated serine protease TMPRSS2 (21q22.2) and the 3' end of ETS family of transcription factors ETV1 (7p21.3) and ERG (21q22.3) in a large frequency of prostate cancer cases raises new questions regarding AR function in prostate cancer. The gene rearrangement is thought to result in AR-induced expression of the suspected ETV1 or ERG oncogenes. |
| Homology | zebrafish (Danio rerio), dog (Canis familiaris), African clawed frog (Xenopus laevis), chimpanzee (Pan troglodytes), mouse (Mus musculus), chicken (Gallus gallus), rat (Rattus norvegicus), rainbow trout (Oncorhynchus mykiss).
No similarity-to-human data found for AR for:
pig (Sus scrofa), cow (Bos taurus), fruit fly (Drosophila melanogaster), worm (Caenorhabditis elegans), baker's yeast (Saccharomyces cerevisiae), tropical clawed frog (Silurana tropicalis), African malaria mosquito (Anopheles gambiae), thale cress (Arabidopsis thaliana), green algae (Chlamydomonas reinhardtii), soybean (Glycine max), barley (Hordeum vulgare), tomato (Lycopersicon esculentum), rice blast fungus (Magnaporthe grisea), rice (Oryza sativa), sugarcane (Saccharum officinarum), loblolly pine (Pinus taeda), corn (Zea mays), wheat (Triticum aestivum), Alicante grape (Vitis vinifera), bread mold (Neurospora crassa), fission yeast (Schizosaccharomyces pombe), sea squirt (Ciona intestinalis), amoeba (Dictyostelium discoideum), A. gosspyii yeast (Ashbya gossypii), K. lactis yeast (Kluyveromyces lactis), medicago trunc (Medicago truncatula), malaria parasite (Plasmodium falciparum), schistosome parasite (Schistosoma mansoni), sorghum (Sorghum bicolor), toxoplasmosis (Toxoplasma gondii). |
| Disease | Androgenic alopecia, spinal and bulbar muscular dystrophy, androgen insensitivity syndrome due to AR mutations, benign prostatic hyperplasia, prostate adenocarcinoma |
| | |
| Entity | Prostate adenocarcinoma (PCa) |
| Disease | PCa is the most commonly diagnosed cancer in American men and the second leading cause of cancer-related deaths. PCa predominantly occurs in the peripheral zone of the human prostate, with roughly 5 to 10% of cases found in the central zone. Disease development involves the temporal and spatial loss of the basal epithelial compartment accompanied by increased proliferation and de-differentiation of the luminal (secretory) epithelial cells. PCa is a slow developing disease that is typically found in men greater than 40 years of age, with an increasing rate of occurrence with increasing age. |
| Prognosis | Serum PSA testing combined with digital-rectal exams (DRE) are used to screen for the presence of disease. Given a positive DRE exam, additional tests including needle core biopsies are taken to histologically assess disease stage and grade. Localized, prostate-restricted disease is theoretically curable with complete removal of the prostate (radical prostatectomy). Patients with extra-prostatic disease are treated with chemotherapy, hormone (androgen ablation) therapy, radiation, and/or antiandrogens; however, no curative treatments are available for non-organ confined, metastatic disease. |
| Cytogenetics | Various forms of aneuploidy. |
| Abnormal Protein | Unknown. |
| Oncogenesis | Alterations in AR function are associated with the development of PCa due to a transition from paracrine AR signaling, traditionally involving the supporting mesenchyme instructing the terminal differentiation of the luminal epithelial cells, to autocrine AR signaling in luminal epithelial cells that promotes cell proliferation. Roughly 10% of PCa patients harbor AR mutations, suggesting that the prevalence of AR mutations, clinically, is low. Mutations that increase the signaling promiscuity of AR, AR gene amplification, as well as alterations in proteins that regulate AR levels/function contribute to de-regulated AR signaling. |
| | |
| Entity | Benign Prostatic Hyperplasia (BPH) |
| Disease | Benign growth of the prostate, primarily occurring in the transitional zone of the prostate, results in urinary obstruction and lower urinary tract symptoms. AR function is associated with increased rates of epithelial cell proliferation, leading to increased size of the prostate gland. Originally thought of as benign prostatic hypertrophy, BPH has since been correctly characterized as a hyperplastic condition. |
| Prognosis | Patients with BPH are primarily treated with 2 types of agents to help reduce the size of the prostate, including Alpha-blockers: Flomax (tamsulosin), Uroxatral (alfuzosin), Hytrin (terazosin), Cardura (doxazosin); and 5-Alpha Reductase Inhibitors: Avodart (dutasteride), Proscar (finasteride). For symptoms unabated by medications, minimally invasive procedures: Transurethral microwave therapy (TUMT) and Transurethral needle ablation (TUNA) exist. More invasive surgeries: Transurethral resection of the prostate (TURP), Open prostatectomy (open surgery), Laser surgery, Transurethral incision of the prostate (TUIP) are available. |
| Oncogenesis | Occurring in the transitional zone of the prostate, it is currently believed that BPH does not lead to or initiate the development of PCa. |
| | |
| Entity | Spinal and bulbar muscular atrophy |
| Note | X-linked recessive form of spinal muscular atrophy |
| Disease | Spinal and bulbar muscular atrophy (SBMA, SMAX1), which is also known as Kennedy disease (KD), is caused by a trinucleotide CAG repeat expansion in exon 1 of the AR gene, resulting in decreased AR mRNA and protein levels. SBMA patients carry 38 to 62 CAG repeats; healthy individuals have 10 to 36. |
| Prognosis | SBMA is a neurodegenerative disease resulting in slow, progressive limb and bulbar muscle weakness, characterized by muscle atrophy due to neuron dysfunction. Also can cause gynecomastia. Current therapies include androgen deprivation therapy to curb the effects of pathologic AR signaling. |
| | |
| Entity | Androgen insensitivity syndrome (AIS) |
| Note | X-linked recessive disorder |
| Disease | Androgen insensitivity syndrome (AIS), Testicular feminization syndrome (TFM). Affected males have female external genitalia, female breast development, blind vagina, absent uterus and female adnexa, and abdominal or inguinal testes, despite a normal male (2A + XY) karyotype. Caused by mutations in the gene for the androgen receptor. |
| | |
| Nomenclature | | Hugo | AR |
| GDB | AR |
| Entrez_Gene | AR 367 androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) |
| Cards |
|---|
| Atlas | ARID685chXq12 |
| GeneCards | AR |
| Ensembl | AR [Search_View] ENSG00000169083 [Gene_View] |
| Genatlas | AR |
| GeneLynx | AR |
| eGenome | AR |
| euGene | 367 |
| Genomic and cartography |
|---|
| GoldenPath | AR - Xq12 chrX:66705408-66860844 + Xq11.2-q12 (hg18-Mar_2006) |
| Ensembl | AR - Xq11.2-q12 [CytoView] |
| NCBI | Mapview |
| OMIM | Disease map [OMIM] |
| HomoloGene | AR |
| Gene and transcription | | Genbank | AF162704 [ ENTREZ ] |
| Genbank | AF321914 [ ENTREZ ] |
| Genbank | AF321915 [ ENTREZ ] |
| Genbank | AF321916 [ ENTREZ ] |
| Genbank | AF321917 [ ENTREZ ] |
| RefSeq | NM_000044 [ SRS ] NM_000044 [ ENTREZ ] |
| RefSeq | NM_001011645 [ SRS ] NM_001011645 [ ENTREZ ] |
| RefSeq | AC_000066 [ SRS ] AC_000066 [ ENTREZ ] |
| RefSeq | NC_000023 [ SRS ] NC_000023 [ ENTREZ ] |
| RefSeq | NT_011669 [ SRS ] NT_011669 [ ENTREZ ] |
| RefSeq | NW_927711 [ SRS ] NW_927711 [ ENTREZ ] |
| AceView | AR AceView - NCBI |
| Unigene | Hs.496240 [ SRS ] Hs.496240 [ NCBI ]
HS496240 [ spliceNest ] |
| Fast-db | 9762 (alternative variants) |
| Protein : pattern, domain, 3D structure |
|---|
| SwissProt | P10275 [ SRS] P10275 [ EXPASY ] P10275 [ INTERPRO ] |
| Prosite | PS00031 NUCLEAR_REC_DBD_1 [ SRS ] PS00031 NUCLEAR_REC_DBD_1 [ Expasy ] |
| Prosite | PS51030 NUCLEAR_REC_DBD_2 [ SRS ] PS51030 NUCLEAR_REC_DBD_2 [ Expasy ] |
| Interpro | IPR001103 Andrgn_rcpt [ SRS ] IPR001103 Andrgn_rcpt [ EBI ] |
| Interpro | IPR008946 Nucl_hormone_rcpt_ligand-bd [ SRS ] IPR008946 Nucl_hormone_rcpt_ligand-bd [ EBI ] |
| Interpro | IPR000536 Nucl_hrmn_rcpt_lig-bd_core [ SRS ] IPR000536 Nucl_hrmn_rcpt_lig-bd_core [ EBI ] |
| Interpro | IPR001628 Znf_hrmn_rcpt [ SRS ] IPR001628 Znf_hrmn_rcpt [ EBI ] |
| Interpro | IPR013088 Znf_NHR/GATA [ SRS ] IPR013088 Znf_NHR/GATA [ EBI ] |
| CluSTr | P10275 |
| Pfam | PF02166 Androgen_recep [ SRS ] PF02166 Androgen_recep [ Sanger ] pfam02166 [ NCBI-CDD ] |
| Pfam | PF00104 Hormone_recep [ SRS ] PF00104 Hormone_recep [ Sanger ] pfam00104 [ NCBI-CDD ] |
| Pfam | PF00105 zf-C4 [ SRS ] PF00105 zf-C4 [ Sanger ] pfam00105 [ NCBI-CDD ] |
| Smart | SM00430 HOLI [EMBL] |
| Smart | SM00399 ZnF_C4 [EMBL] |
| Prodom | PD000035 Znf_C4steroid[INRA-Toulouse] |
| Prodom | P10275 ANDR_HUMAN [ Domain structure ] P10275 ANDR_HUMAN [ sequences sharing at least 1 domain ] |
| Blocks | P10275 |
| PDB | 1E3G [ SRS ] 1E3G [ PdbSum ], 1E3G [ IMB ] 1E3G [ RSDB ] |
| PDB | 1GS4 [ SRS ] 1GS4 [ PdbSum ], 1GS4 [ IMB ] 1GS4 [ RSDB ] |
| PDB | 1T5Z [ SRS ] 1T5Z [ PdbSum ], 1T5Z [ IMB ] 1T5Z [ RSDB ] |
| PDB | 1T63 [ SRS ] 1T63 [ PdbSum ], 1T63 [ IMB ] 1T63 [ RSDB ] |
| PDB | 1T65 [ SRS ] 1T65 [ PdbSum ], 1T65 [ IMB ] 1T65 [ RSDB ] |
| PDB | 1XJ7 [ SRS ] 1XJ7 [ PdbSum ], 1XJ7 [ IMB ] 1XJ7 [ RSDB ] |
| PDB | 1XOW [ SRS ] 1XOW [ PdbSum ], 1XOW [ IMB ] 1XOW [ RSDB ] |
| PDB | 1XQ3 [ SRS ] 1XQ3 [ PdbSum ], 1XQ3 [ IMB ] 1XQ3 [ RSDB ] |
| PDB | 1Z95 [ SRS ] 1Z95 [ PdbSum ], 1Z95 [ IMB ] 1Z95 [ RSDB ] |
| PDB | 2AM9 [ SRS ] 2AM9 [ PdbSum ], 2AM9 [ IMB ] 2AM9 [ RSDB ] |
| PDB | 2AMA [ SRS ] 2AMA [ PdbSum ], 2AMA [ IMB ] 2AMA [ RSDB ] |
| PDB | 2AMB [ SRS ] 2AMB [ PdbSum ], 2AMB [ IMB ] 2AMB [ RSDB ] |
| PDB | 2AO6 [ SRS ] 2AO6 [ PdbSum ], 2AO6 [ IMB ] 2AO6 [ RSDB ] |
| PDB | 2AX6 [ SRS ] 2AX6 [ PdbSum ], 2AX6 [ IMB ] 2AX6 [ RSDB ] |
| PDB | 2AX7 [ SRS ] 2AX7 [ PdbSum ], 2AX7 [ IMB ] 2AX7 [ RSDB ] |
| PDB | 2AX8 [ SRS ] 2AX8 [ PdbSum ], 2AX8 [ IMB ] 2AX8 [ RSDB ] |
| PDB | 2AX9 [ SRS ] 2AX9 [ PdbSum ], 2AX9 [ IMB ] 2AX9 [ RSDB ] |
| PDB | 2AXA [ SRS ] 2AXA [ PdbSum ], 2AXA [ IMB ] 2AXA [ RSDB ] |
| PDB | 2HVC [ SRS ] 2HVC [ PdbSum ], 2HVC [ IMB ] 2HVC [ RSDB ] |
| PDB | 2OZ7 [ SRS ] 2OZ7 [ PdbSum ], 2OZ7 [ IMB ] 2OZ7 [ RSDB ] |
| PDB | 2PIO [ SRS ] 2PIO [ PdbSum ], 2PIO [ IMB ] 2PIO [ RSDB ] |
| PDB | 2PIP [ SRS ] 2PIP [ PdbSum ], 2PIP [ IMB ] 2PIP [ RSDB ] |
| PDB | 2PIQ [ SRS ] 2PIQ [ PdbSum ], 2PIQ [ IMB ] 2PIQ [ RSDB ] |
| PDB | 2PIR [ SRS ] 2PIR [ PdbSum ], 2PIR [ IMB ] 2PIR [ RSDB ] |
| PDB | 2PIT [ SRS ] 2PIT [ PdbSum ], 2PIT [ IMB ] 2PIT [ RSDB ] |
| PDB | 2PIU [ SRS ] 2PIU [ PdbSum ], 2PIU [ IMB ] 2PIU [ RSDB ] |
| PDB | 2PIV [ SRS ] 2PIV [ PdbSum ], 2PIV [ IMB ] 2PIV [ RSDB ] |
| PDB | 2PIW [ SRS ] 2PIW [ PdbSum ], 2PIW [ IMB ] 2PIW [ RSDB ] |
| PDB | 2PIX [ SRS ] 2PIX [ PdbSum ], 2PIX [ IMB ] 2PIX [ RSDB ] |
| PDB | 2PKL [ SRS ] 2PKL [ PdbSum ], 2PKL [ IMB ] 2PKL [ RSDB ] |
| PDB | 2PNU [ SRS ] 2PNU [ PdbSum ], 2PNU [ IMB ] 2PNU [ RSDB ] |
| PDB | 2Q7I [ SRS ] 2Q7I [ PdbSum ], 2Q7I [ IMB ] 2Q7I [ RSDB ] |
| PDB | 2Q7J [ SRS ] 2Q7J [ PdbSum ], 2Q7J [ IMB ] 2Q7J [ RSDB ] |
| PDB | 2Q7K [ SRS ] 2Q7K [ PdbSum ], 2Q7K [ IMB ] 2Q7K [ RSDB ] |
| PDB | 2Q7L [ SRS ] 2Q7L [ PdbSum ], 2Q7L [ IMB ] 2Q7L [ RSDB ] |
| HPRD | 02437 |
| Protein Interaction databases |
|---|
| DIP | P10275 |
| IntAct | P10275 |
| Polymorphism : SNP, mutations, diseases |
|---|
| OMIM | 176807;300068;300633;313200;313700 [ map ] |
| GENECLINICS | 176807;300068;300633;313200;313700 |
| SNP | AR [dbSNP-NCBI] |
| SNP | NM_000044 [SNP-NCI] |
| SNP | NM_001011645 [SNP-NCI] |
| SNP | AR [GeneSNPs - Utah] AR] [HGBASE - SRS] |
| HAPMAP | AR [HAPMAP] |
| COSMIC | AR [Somatic mutation (COSMIC-CGP-Sanger)] |
| HGMD | AR |
| General knowledge |
|---|
| Family Browser | AR [UCSC Family Browser] |
| SOURCE | NM_000044 |
| SOURCE | NM_001011645 |
| SMD | Hs.496240 |
| SAGE | Hs.496240 |
| GO | transcription factor activity [Amigo] transcription factor activity |
| GO | receptor activity [Amigo] receptor activity |
| GO | androgen receptor activity [Amigo] androgen receptor activity |
| GO | androgen receptor activity [Amigo] androgen receptor activity |
| GO | androgen binding [Amigo] androgen binding |
| GO | nucleus [Amigo] nucleus |
| GO | cytoplasm [Amigo] cytoplasm |
| GO | regulation of transcription, DNA-dependent [Amigo] regulation of transcription, DNA-dependent |
| GO | transport [Amigo] transport |
| GO | signal transduction [Amigo] signal transduction |
| GO | cell-cell signaling [Amigo] cell-cell signaling |
| GO | sex differentiation [Amigo] sex differentiation |
| GO | zinc ion binding [Amigo] zinc ion binding |
| GO | cell proliferation [Amigo] cell proliferation |
| GO | cell growth [Amigo] cell growth |
| GO | prostate gland development [Amigo] prostate gland development |
| GO | sequence-specific DNA binding [Amigo] sequence-specific DNA binding |
| GO | metal ion binding [Amigo] metal ion binding |
| GO | protein dimerization activity [Amigo] protein dimerization activity |
| PubGene | AR |
| TreeFam | AR |
| Other databases |
|---|
| Probes |
|---|
| Probe | AR Related clones (RZPD - Berlin) |
| PubMed |
|---|
| PubMed | 499 Pubmed reference(s) in LocusLink |
| Physiology and pathophysiology of androgen action. |
| Hiort O, Holterhus PM, Nitsche EM |
| Bailliere's clinical endocrinology and metabolism. 1998 ; 12 (1) : 115-132. |
| PMID 9890064 |
| |
| Molecular genetics of prostate cancer. |
| Abate-Shen C, Shen MM |
| Genes & development. 2000 ; 14 (19) : 2410-2434. |
| PMID 11018010 |
| |
| Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. |
| Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, Helin HJ, Jˆ§nne OA, Vihinen M, Palvimo JJ, Koivisto PA |
| Laboratory investigation; a journal of technical methods and pathology. 2002 ; 82 (11) : 1591-1598. |
| PMID 12429819 |
| |
| Formation of the androgen receptor transcription complex. |
| Shang Y, Myers M, Brown M |
| Molecular cell. 2002 ; 9 (3) : 601-610. |
| PMID 11931767 |
| |
| Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? |
| Litvinov IV, De Marzo AM, Isaacs JT |
| The Journal of clinical endocrinology and metabolism. 2003 ; 88 (7) : 2972-2982. |
| PMID 12843129 |
| |
| Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. |
| Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T |
| The Journal of steroid biochemistry and molecular biology. 2004 ; 92 (4) : 221-236. |
| PMID 15663986 |
| |
| [Paradigm shift in clinical trials for neurodegenerative diseases] |
| Katsuno M, Banno H, Suzuki K, Takeuchi Y, Sobue G |
| Brain and nerve = Shinkei kenkyu no shinpo. 2007 ; 59 (4) : 367-374. |
| PMID 17447523 |
| |
